Participants in new trial lost weight and did not suffer gastrointestinal byproducts associated with GLP-1 medicines ...

Enveda's new drug has seen promising Phase I trial results.

A once-daily weight-loss pill is attracting attention after a major clinical trial found it outperformed oral semaglutide, the tablet form of the drug behind Ozempic and Wegovy, in key measures of ...

So naturally, when the Wegovy pill came online—a tablet form of semaglutide, the same ingredient found in Ozempic and the ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. It's here. The first no-fuss once-daily GLP-1 pill for weight loss, Eli Lilly's Foundayo, was approved ...

Phase 2 trials of aleniglipron show up to 12% weight loss via an oral tablet, offering a small-molecule alternative to ...

Could ENV-308 help maintain weight loss after GLP-1s? Learn what early trial results show about its potential affects on ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

Add Yahoo as a preferred source to see more of our stories on Google. (NewsNation) — Spending hours in the gym to get fit may one day be a thing of the past, as a pill designed to mimic some of the ...

Learn about Foundayo (orforglipron), the once-daily oral GLP-1 weight loss pill. Read about its effectiveness, side effects, cost and how it compares to Wegovy and other GLP-1s.

The future of weight loss treatment is looking to get easier to swallow. Several research teams and pharmaceutical companies are developing promising GLP-1-based drugs that come in a pill rather than ...